Colchicine

Evidence Level: L5

Predicted Indications: 2

Colchicine

Pharmacist Assessment Report

Colchicine: Microtubule-disrupting agent (tubulin binder) → Plasmodium falciparum malaria

One-Sentence Summary

Colchicine is a tubulin-binding, microtubule-disrupting agent registered in Australia as an oral tablet. The TxGNN model predicts it may be relevant for Plasmodium falciparum malaria, but there are 0 clinical trials and 2 publications, and neither studies colchicine against this disease. Evidence for this prediction is limited to the model output.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Plasmodium falciparum malaria
TxGNN Prediction Score	0.9960
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, colchicine binds tubulin and disrupts microtubules.

Microtubules are essential to the parasite’s cell division, so a link to P. falciparum is biologically plausible. The two retrieved papers are indirect. One is a laboratory study of curcumin (not colchicine) that disrupts microtubules in P. falciparum. The other examines expression of the parasite’s pfmdr1 gene in mammalian cells and its effect on chloroquine susceptibility. Neither tests colchicine as an antimalarial in people.

This is a plausible but unproven link. Colchicine also has a narrow therapeutic index and many drug interactions, which are a concern for any anti-infective use.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23505424	2013	In vitro study	PloS one	Curcumin (not colchicine) disrupted microtubules in P. falciparum cells
7511206	1994	In vitro / cell-based study	Molecular and cellular biology	Expressing the parasite pfmdr1 gene in mammalian cells increased chloroquine susceptibility

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 3410L	Colcine	Tablet 500 micrograms	Not recorded in the local data

Safety Considerations

Drug Interactions: The interaction query found 100 interacting drugs in total. Examples rated Major include aprepitant, clarithromycin, cobicistat, deferiprone, eliglustat, rolapitant, rosuvastatin and simvastatin. Examples rated Moderate include chloroquine, cimetidine, metronidazole, miconazole, ticagrelor and disulfiram. Chloroquine is relevant here because it is a standard antimalarial.

For warnings and contraindications, please refer to the TGA-approved Product Information (PI).

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on the model score alone. No study directly examines colchicine in P. falciparum malaria, and the safety margin is narrow, so there is no basis to proceed.

To proceed, the following is needed:

Laboratory data showing colchicine activity against P. falciparum at concentrations achievable in humans
Detailed mechanism of action data
Review of the TGA Product Information for warnings and contraindications
A drug interaction assessment against standard antimalarials, particularly chloroquine
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.